LillyDirect (Zepbound) vs Remedy Meds (2026): prices, structure, verdict

On tirzepatide, Remedy Meds↗ is cheaper: $399 versus $449 a month all-in — a $50 monthly gap, $600 across a year of maintenance dosing, and Remedy Meds's figure is dose-flat while LillyDirect (Zepbound)↗'s structure is not.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only Remedy Meds has a rankable figure: $299 a month all-in; LillyDirect (Zepbound) does not offer semaglutide.

§ Side by side

§ Each record, read aloud

The two records, condensed

LillyDirect (Zepbound): the record, condensed

Start with the load-bearing figure: $449 a month, all-in, is what LillyDirect (Zepbound) charges for tirzepatide at the 10 mg basis. Pricing steps with the dose here: from $299 at entry to $449 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $1,800 a year, which is why every ranking on this site uses the larger number.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #0 of 17 in the verified tirzepatide index — $234/month above the floor (NexLife↗, $215) — and sits $0 over the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $5,388.

Operationally at LillyDirect (Zepbound): shipping included (or same-day retail pickup); commitment 45-day refill cadence to keep pricing; cancellation no subscription; refill-window rules apply; pharmacy named (Eli Lilly direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-09. The full record with source and archive links: the LillyDirect (Zepbound) page · visit LillyDirect (Zepbound) ↗

Remedy Meds: the record, condensed

Start with the load-bearing figure: $399 a month, all-in, is what Remedy Meds charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $399 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #15 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

Start with the load-bearing figure: $299 a month, all-in, is what Remedy Meds charges for semaglutide at the 2.4 mg basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Remedy Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #19 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at Remedy Meds: shipping included; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Remedy Meds page · visit Remedy Meds ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $399 (Remedy Meds) against $449 (LillyDirect (Zepbound)). $50 a month sounds survivable; $600 a year is a decision.

Structure sharpens the gap: Remedy Meds’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while LillyDirect (Zepbound)’s is not — so Remedy Meds’s number is a ceiling and LillyDirect (Zepbound)’s advertised entry ($299) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Translate the $50/month spread into medication: $600 a year equals roughly 1.5 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: LillyDirect (Zepbound) $449/mo month-to-month versus Remedy Meds $399/mo month-to-month. Same winner on both bases — Remedy Meds leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: LillyDirect (Zepbound) $1,347 monthly; Remedy Meds $1,197 monthly — best path favors Remedy Meds by $150. 6 months: LillyDirect (Zepbound) $2,694 monthly; Remedy Meds $2,394 monthly — best path favors Remedy Meds by $300. 12 months: LillyDirect (Zepbound) $5,388 monthly; Remedy Meds $4,788 monthly — best path favors Remedy Meds by $600. 24 months: LillyDirect (Zepbound) $10,776 monthly; Remedy Meds $9,576 monthly — best path favors Remedy Meds by $1,200.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: LillyDirect (Zepbound) publishes “50 states”; Remedy Meds publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: LillyDirect (Zepbound) names its network (Eli Lilly direct / retail partners); Remedy Meds does not, which shifts the burden of verification onto your intake questions.

Exit terms: LillyDirect (Zepbound) — 45-day refill cadence to keep pricing; no subscription; refill-window rules apply. Remedy Meds — unknown; not published.

Evidence: LillyDirect (Zepbound) source-verified (captured 2026-08-09); Remedy Meds third-party reported (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between LillyDirect (Zepbound) and Remedy Meds

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (LillyDirect (Zepbound): no subscription; refill-window rules apply; Remedy Meds: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings